Egrifta (Tesamorelin) HSA/FSA Eligibility and Submission Guide

Is Egrifta Covered by HSA and FSA Plans?

Egrifta (tesamorelin) is eligible for reimbursement through both Health Savings Accounts and Flexible Spending Accounts when prescribed by a licensed clinician for a qualified medical purpose. The IRS classifies prescription drugs as medical expenses under IRS Publication 502, and tesamorelin carries FDA approval as a prescription-only injectable. Because the drug requires a valid prescription, it clears the statutory threshold automatically.

What the IRS Says About Prescription Drug Reimbursement

Under IRS Publication 502, "the cost of prescription drugs you take for medical care" constitutes a deductible medical expense. Tesamorelin is dispensed exclusively by prescription and is classified by the FDA as a growth hormone-releasing factor (GRF) analogue. The FDA granted Egrifta SV approval in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the current formulation (Egrifta SV) received supplemental approval in 2019 for a simplified reconstitution method. Both the original and SV formulations share the same active molecule and carry the same IRS eligibility status. FDA approval records confirm the prescription-only classification.

HSA vs. FSA: Key Differences for Tesamorelin Users

HSA funds roll over indefinitely, making them useful for high-cost injectables like Egrifta when you accumulate funds over multiple benefit years. FSA funds typically expire at year-end, though many employers allow a $660 carryover or a 2.5-month grace period. Tesamorelin's high monthly cost (often $6,000 or more at wholesale acquisition cost) means most users will need to combine HSA/FSA reimbursement with additional access programs. The 2026 HSA contribution ceiling is $4,300 for self-only coverage and $8,550 for family coverage per IRS Revenue Procedure 2025-19.

Which Plans Qualify?

To use an HSA, you must be enrolled in a High-Deductible Health Plan (HDHP). The minimum deductible for HDHP qualification in 2026 is $1,650 (self-only) or $3,300 (family). FSAs are available through most employer-sponsored plans regardless of deductible structure. Neither account type restricts coverage by drug category as long as the drug is prescribed and FDA-approved.

How to Submit an HSA or FSA Claim for Egrifta

Submitting a successful claim takes four steps: obtain the correct documentation, complete your plan's reimbursement form, submit within the plan's deadline, and retain copies for IRS substantiation. Missing any step is the most common reason claims are denied or delayed.

Step 1: Gather Required Documentation

Your plan administrator will need at minimum:

• An itemized pharmacy receipt showing the drug name (tesamorelin or Egrifta SV), dispensing date, quantity dispensed, and amount charged.
• The prescriber's name, NPI number, and practice address.
• A diagnosis code (ICD-10). For HIV-associated lipodystrophy, the relevant code is E88.1 (lipodystrophy, not elsewhere classified) combined with B20 (HIV disease) on the prescriber's letter. Confirm the exact code with your prescribing clinician.
• A letter of medical necessity (LMN) if your plan requires one. Many FSA third-party administrators request an LMN for specialty injectables. The LMN should state the diagnosis, why tesamorelin is medically necessary, and the anticipated duration of therapy. Clinical trial evidence from the key Phase III studies (N=816) supports medical necessity documentation.

Step 2: Complete the Reimbursement Form

Most plan administrators offer an online portal. Paper forms remain available from all major FSA vendors. The form typically asks for:

• Date of service (use the dispensing date on the pharmacy receipt).
• Provider type (pharmacy).
• Amount requested.
• Patient relationship to account holder.

Do not list a physician office visit and the drug dispensing on the same claim line. Separate line items process faster and reduce audit flags.

Step 3: Submit and Track

Submit electronically when possible. Paper submissions at major FSA vendors average 10 to 15 business days for processing; electronic submissions typically resolve in 3 to 5 business days. Keep a submission confirmation number. The IRS requires substantiation records for HSA distributions for up to 3 years after the tax return filing date per IRS Notice 2004-50.

Step 4: Handle a Denial

If your claim is denied, request the denial reason in writing. Common reasons include missing NDC (National Drug Code) on the receipt, an unrecognized drug name (ask your pharmacy to list "tesamorelin" alongside the brand), or a benefits-year mismatch. Resubmit with corrections within 60 days of the denial date. A formal appeal is always an option and should cite the IRS Publication 502 prescription-drug category.

Clinical Background: Why Tesamorelin Is Prescribed

Understanding the clinical rationale strengthens your letter of medical necessity and helps your plan administrator recognize the drug as a legitimate medical expense rather than an elective purchase.

FDA-Approved Indication

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved Egrifta in November 2010 specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition in which antiretroviral therapy (ART) alters adipose tissue distribution. This is a narrow, diagnosis-specific indication, not a general anti-aging or body-composition use. The FDA label for Egrifta SV restricts use to this population.

Key Phase III Evidence

The approval rested on two randomized, placebo-controlled Phase III trials. In the combined dataset (N=816), tesamorelin 2 mg subcutaneously once daily for 26 weeks produced a statistically significant reduction in visceral adipose tissue (VAT) by approximately 18% versus placebo Falutz et al., NEJM 2007. A 52-week extension confirmed that VAT reduction was maintained with continued therapy and reversed upon discontinuation. This reversal pattern is one reason prescribers document ongoing medical necessity for HSA/FSA purposes, because therapy is generally long-term.

Metabolic Relevance

Excess visceral adiposity in HIV-related lipodystrophy is associated with elevated triglycerides, insulin resistance, and increased cardiovascular risk. A secondary analysis published in JAMA Internal Medicine (2012) found that tesamorelin-treated patients showed significant reductions in triglycerides alongside VAT reduction. Cardiovascular risk reduction in this population has been documented in research supported by the NIH-funded ACTG A5263 trial, strengthening the argument that the drug is medically necessary rather than cosmetic.

How to Get Egrifta Cheaper: A Layered Cost-Reduction Strategy

The monthly wholesale acquisition cost of Egrifta SV can exceed $6,000, which places it well above the 2026 HSA contribution ceiling for most individuals. A layered approach combining HSA/FSA dollars with manufacturer support and specialty-pharmacy programs is the most practical path to affordability.

Layer 1: Theratechnologies Patient Assistance Program

Theratechnologies operates a patient-access program for Egrifta SV. Eligibility criteria and benefit levels change; contact the manufacturer directly at their medically designated access line for 2026 terms. Patients with commercial insurance who meet income thresholds may receive co-pay support that substantially reduces out-of-pocket cost before HSA/FSA reimbursement is even needed. The FDA's access-program guidance outlines what manufacturers are permitted to provide.

Layer 2: Specialty Pharmacy Pricing

Egrifta SV is dispensed through specialty pharmacies. Specialty pharmacies contract with manufacturers for preferred pricing. Requesting a price comparison across two or three contracted specialty pharmacies before filling a new prescription may yield a lower cash price if your insurer does not cover the drug. Some specialty pharmacies also offer in-house assistance programs for patients without insurance coverage.

Layer 3: HSA/FSA Stacking

After applying any manufacturer co-pay card or assistance program benefit, use HSA or FSA funds to cover the remaining patient-responsibility balance. The IRS does not prohibit stacking HSA/FSA reimbursement on top of manufacturer discounts, as long as the HSA/FSA funds pay actual out-of-pocket costs you incurred, not costs already covered by insurance or another payer. This distinction matters: if the manufacturer co-pay card zeroes out your cost entirely, there is no remaining eligible expense to submit to your HSA/FSA.

Layer 4: Prior Authorization and Appeals

Most commercial payers and Medicare Part D require prior authorization for tesamorelin. A denied prior authorization increases out-of-pocket exposure. If your insurer denies coverage, your prescribing clinician can initiate a formal appeal citing the FDA-approved labeling, the key trial data, and the AACE position on growth hormone-related disorders. A successful appeal moves the drug onto your plan's formulary, reducing your cost share and making HSA/FSA funds go further.

Documentation Your Prescriber Should Provide

A strong letter of medical necessity reduces claim denials and accelerates reimbursement. Ask your prescriber to include the following elements.

Required LMN Elements

1. Patient full name and date of birth.
2. Diagnosis with ICD-10 code (e.g., E88.1 and B20 for HIV-associated lipodystrophy).
3. Drug name: tesamorelin (Egrifta SV), 2 mg subcutaneously daily.
4. Clinical rationale: how the drug addresses the diagnosed condition.
5. Duration: tesamorelin therapy is typically ongoing because VAT returns after discontinuation, as confirmed in Falutz et al. (2010).
6. Prescriber NPI, signature, and date.
7. A statement that the drug is not being used for cosmetic purposes.

Supporting Lab Data

Including baseline VAT imaging (CT or DEXA) and triglyceride levels strengthens the LMN. Payers sometimes request evidence that lipodystrophy was confirmed objectively before approving coverage or reimbursement. Published thresholds from the Endocrine Society clinical practice guideline on HIV and endocrine complications can anchor the clinical thresholds cited in the LMN.

IRS Rules That Govern HSA/FSA Reimbursement of Prescription Drugs

The Tax Cuts and Jobs Act of 2017 and subsequent IRS guidance confirm that prescription drugs purchased in any form, including specialty injectables, qualify as medical expenses. The CARES Act (2020) expanded OTC drug eligibility but did not change the prescription-drug category. Tesamorelin's prescription-only status means it was always eligible and remains so in 2026.

Key IRS Documents

• IRS Publication 502 (2025 edition): The definitive list of qualified medical expenses.
• IRS Notice 2004-50: HSA distribution substantiation requirements.
• IRS Revenue Procedure 2025-19: 2026 HDHP and HSA contribution limits.

Record Retention

Keep all pharmacy receipts, EOBs (Explanation of Benefits), and LMN copies for at least 3 years after you file the tax return for the year of the distribution. An IRS audit of an HSA distribution requires you to show the expense was a qualified medical expense at the time of the withdrawal.

Special Considerations for 2026

Several regulatory and program factors make 2026 distinct from prior years.

Medicare Part D Redesign

The Inflation Reduction Act restructured Medicare Part D beginning in 2025, capping annual out-of-pocket drug costs at $2,000 for Part D enrollees. Medicare beneficiaries using Egrifta through Part D may find their out-of-pocket exposure substantially lower than in prior years. However, HSAs are not compatible with Medicare enrollment. FSAs tied to Medicare Advantage plans may still be available depending on plan design. The CMS Part D redesign overview details the changes.

IRA Drug Price Negotiation

Tesamorelin is not currently on the CMS drug-price negotiation list for 2025 or 2026 publication cycles. Status may change. Monitor CMS negotiation announcements for updates.

Biosimilar Pipeline

No FDA-approved biosimilar for tesamorelin exists as of early 2026. When a biosimilar enters the market, it will carry the same IRS prescription-drug eligibility as the reference product, potentially at lower cost.

The HealthRX Access Framework for tesamorelin cost management follows a four-layer sequence: (1) confirm prior authorization and insurance coverage first; (2) apply manufacturer co-pay or patient-assistance program benefits; (3) submit remaining out-of-pocket costs to HSA or FSA; (4) retain all documentation for IRS substantiation and plan-year appeals. Patients who skip layer one and attempt HSA/FSA-only coverage of the full drug cost often exhaust their annual contribution limit by month two.

Frequently Asked Questions